Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation

Pharmacologic SPAF cost-effectiveness models have been extensively reported, but many may have flaws giving reason for decision makers to use caution. We provide 10 recommendations to avoid common flaws in SPAF cost-effectiveness models.